Eagle Pharmaceuticals (EGRX)

$EGRX Great news, the Trial delayed to 2027.

$EGRX I have 5,000 shares here

$EGRX cal02 trial status now shows suspended

$EGRX Small position

$EGRX 🚨 NASDAQ: JFB - Watching $7 Into the 3PM? 🚨 Seeing increased chatter around a potential large-scale contract (rumored $1B+ - not confirmed). Volume remains elevated, and momentum looks intact. Price moved cleanly through $6.18, and eyes are now on the $7 level as we head toward the afternoon session. With a low float, growing project pipeline, and strong price action, this is definitely one to keep on the radar. Technical setup looks solid, sentiment continues to build - monitoring closely. 📈 ⚠️ Not a recommendation. Just my perspective - always do your own research.

$EGRX stockholders filed a claim against Eagle Pharmaceuticals for allegedly overstating revenue and failing to disclose issues related to PEMFEXY® sales and financial reporting. You can join this case to be notified about any new information: https://11th.com/cases/eagle-investor-suit

$EGRX So Fidelity "does not allow purchasing of this stock due to limited company information and / or the risk associated with this security" So how does Stocktwits rate this #1 on their Russell top 25? Also, only 280 shares traded Thursday. Someone care to explain. Thanks

$EGRX Here's why they might be doing this: Immediate Capital for Debt Repayment: The $69 million upfront payment will help Eagle Pharmaceuticals address its existing debt obligations. This includes repaying a term loan and a revolving credit facility. Reducing debt can help stabilize the company's finances and potentially reduce interest payments, which could improve overall financial health. Non-Dilutive Funding: By opting for a royalty sale instead of issuing new equity, Eagle avoids diluting its existing shareholders. This allows them to raise funds without negatively impacting the value of existing stock, which is often a concern for investors. Focus on R&D: The company seems to be prioritizing its ongoing research and development programs, such as the CAL02 and EA 114 drugs. These projects represent future growth potential, and the capital infusion allows Eagle to continue investing in these long-term programs without diverting funds from them.

$EGRX Eagle Pharmaceuticals announces $69M pact to monetize Bendeka royalties Eagle Pharmaceuticals announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds managed by Blue Owl Capital, dated March 31 to sell the royalty interest in annual net sales of Bendeka in the United States for an aggregate purchase price of $69M before transaction costs. Bendeka is a ready-to-dilute liquid, low-volume and short-time ten-minute infusion formulation of bendamustine. It is approved for the treatment of chronic lymphocytic leukemia and for the treatment of indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Under the terms of the agreement, Eagle will receive $69M before transaction costs as an upfront payment in exchange for a prespecified amount of Eagle's royalty interest for net sales of Bendeka for the quarter ending December 31, 2024, and 100% of the royalty interest thereafter, up to an aggregate cap of up to 1.3 times the purchase price, depending on when the royalty cap is achieved, after which all future royalty payments from net sales of Bendeka will revert back to Eagle.

$ICON still on my screener still a buyer Monday $MSTZ also on my screener massive inflows I’m still nibbling at these prices Monday $EGRX possibly opening a new position in this bad boy this week. Insane momentum YTD